Reaction
Abdominal Lymphadenopathy reporting signals
As of the last recalculation, Abdominal Lymphadenopathy appears in 847 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is CABOTEGRAVIR (PRR 81.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cabotegravir | 26 | 81.6 | 81.9 |
| Goserelin | 30 | 56.9 | 57.0 |
| Polatuzumab Vedotin | 18 | 46.3 | 46.4 |
| Bendamustine Hcl | 24 | 39.1 | 39.2 |
| Everolimus Tablets | 20 | 30.0 | 30.0 |
| Lisdexamfetamine Dimesylate | 33 | 25.5 | 25.6 |
| Fulvestrant | 33 | 25.5 | 25.5 |
| Exemestane | 21 | 24.7 | 24.7 |
| Pyrazinamide | 9 | 23.8 | 23.8 |
| Brentuximab Vedotin | 9 | 21.8 | 21.8 |
| Obinutuzumab | 14 | 21.2 | 21.3 |
| Bendamustine Hydrochloride | 10 | 20.8 | 20.8 |
| Fesoterodine Fumarate | 9 | 20.6 | 20.6 |
| Ifosfamide | 17 | 19.8 | 19.8 |
| Basiliximab | 9 | 19.0 | 19.0 |
| Felodipine Extended-Release Tablets | 8 | 17.4 | 17.4 |
| Felodipine | 8 | 17.4 | 17.4 |
| Regorafenib | 8 | 17.1 | 17.1 |
| Zoledronic Acid | 27 | 17.0 | 17.1 |
| Acalabrutinib | 8 | 16.4 | 16.4 |
| Sorafenib | 13 | 15.6 | 15.6 |
| Isoniazid | 10 | 15.3 | 15.3 |
| Everolimus | 30 | 15.0 | 15.0 |
| Ibrutinib | 46 | 14.7 | 14.7 |
| Trametinib | 14 | 14.5 | 14.5 |
| Dabrafenib | 12 | 14.2 | 14.2 |
| Capecitabine | 48 | 13.6 | 13.6 |
| Vedolizumab | 42 | 12.6 | 12.6 |
| Venetoclax | 30 | 12.4 | 12.4 |
| Desoximetasone | 9 | 11.7 | 11.7 |
| Niraparib | 10 | 11.2 | 11.2 |
| Romiplostim | 6 | 9.9 | 9.9 |
| Tofacitinib Citrate | 5 | 9.4 | 9.4 |
| Abiraterone | 4 | 7.2 | 7.3 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 5 | 6.8 | 6.8 |
| Enzalutamide | 14 | 5.9 | 5.9 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 5.6 | 5.6 |
| Abiraterone Acetate | 9 | 5.4 | 5.4 |